CY1842A - Hybrid interferons - Google Patents

Hybrid interferons

Info

Publication number
CY1842A
CY1842A CY184296A CY184296A CY1842A CY 1842 A CY1842 A CY 1842A CY 184296 A CY184296 A CY 184296A CY 184296 A CY184296 A CY 184296A CY 1842 A CY1842 A CY 1842A
Authority
CY
Cyprus
Prior art keywords
interferons
hybrid interferons
novel hybrid
hybrid
interferon
Prior art date
Application number
CY184296A
Other languages
English (en)
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858514723A external-priority patent/GB8514723D0/en
Priority claimed from GB858514722A external-priority patent/GB8514722D0/en
Priority claimed from GB858514726A external-priority patent/GB8514726D0/en
Priority claimed from GB858514725A external-priority patent/GB8514725D0/en
Priority claimed from GB858514724A external-priority patent/GB8514724D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of CY1842A publication Critical patent/CY1842A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon
CY184296A 1985-06-11 1996-03-08 Hybrid interferons CY1842A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB858514723A GB8514723D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514722A GB8514722D0 (en) 1985-06-11 1985-06-11 Hybrid interferon
GB858514726A GB8514726D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptides
GB858514725A GB8514725D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptide
GB858514724A GB8514724D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon

Publications (1)

Publication Number Publication Date
CY1842A true CY1842A (en) 1996-03-08

Family

ID=27516593

Family Applications (1)

Application Number Title Priority Date Filing Date
CY184296A CY1842A (en) 1985-06-11 1996-03-08 Hybrid interferons

Country Status (20)

Country Link
US (2) US4885166A (xx)
EP (1) EP0205404B1 (xx)
JP (2) JPH0655759B2 (xx)
KR (1) KR920002267B1 (xx)
AT (1) ATE78262T1 (xx)
AU (1) AU598196B2 (xx)
CA (1) CA1285507C (xx)
CY (1) CY1842A (xx)
DE (1) DE3685996T2 (xx)
DK (1) DK168794B1 (xx)
FI (1) FI90983C (xx)
GR (1) GR861497B (xx)
HK (1) HK99895A (xx)
HU (1) HU203255B (xx)
IE (1) IE57865B1 (xx)
IL (1) IL79085A (xx)
NO (1) NO175602C (xx)
NZ (1) NZ216485A (xx)
PT (1) PT82736B (xx)
SG (1) SG25195G (xx)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0331635A3 (en) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
WO1992004455A1 (en) * 1990-08-29 1992-03-19 Genetics Institute, Inc. Multidomain hematopoiesis stimulators
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
DE69222013T2 (de) * 1991-12-16 1998-01-29 Ciba Geigy Ag Endoplasmatisches Retikulum-ständige rekombinante dibasische Endoprotease und deren Verwendungen
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
DK0584343T3 (da) * 1992-03-10 1999-09-13 Jolla Cancer Res Found Rekombinant alkalisk phosphatase fra kalvetarme
TW218846B (xx) * 1992-04-07 1994-01-11 Ciba Geigy
JPH078215A (ja) * 1993-04-30 1995-01-13 Kawasaki Steel Corp ドコサヘキサエン酸含有海洋性微細藻類食品素材およびその製造方法
TW249202B (xx) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
ATE207538T1 (de) 1995-02-09 2001-11-15 Behringwerke Ag Verfahren zur produktion von proteinen
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
US6685933B1 (en) * 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
EE04967B1 (et) 1998-10-16 2008-02-15 Biogen, Incorporated Glkoslitud interferoon-beeta, selle kasutamineja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
AU2002225870B2 (en) * 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
KR20040053291A (ko) * 2001-11-09 2004-06-23 바이오메디신즈 인코포레이티드 오메가 인터페론을 이용한 질환 치료 방법
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
KR20050086498A (ko) * 2002-11-18 2005-08-30 맥시겐, 인크. 인터페론-알파 폴리펩티드 및 접합체
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2008507298A (ja) * 2004-05-19 2008-03-13 マキシジェン， インコーポレイテッド インターフェロンαポリペプチドおよび結合体
JP2008509889A (ja) * 2004-06-30 2008-04-03 イージェン コーポレーション ペグ化インターフェロンα−１ｂ
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
MX2007014524A (es) * 2005-05-18 2008-02-07 Maxygen Inc Polipeptidos desarrollados de interferon-alfa.
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
SI2634243T1 (en) 2006-07-14 2018-01-31 Patheon Holdings I B.V. Improved cell culture process
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
KR101532797B1 (ko) 2006-12-06 2015-07-01 메디뮨 엘엘씨 인터페론 알파 유도성 약력학적 마커
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
NZ580686A (en) * 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
EP2068924A4 (en) 2007-05-03 2011-07-20 Medimmune Llc INTERFERON ALPHA INDUCED PHARMACODYNAMIC MARKERS
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
ES2557352T3 (es) 2007-11-05 2016-01-25 Medimmune, Llc Métodos de tratamiento de la esclerodermia
EP2848702A1 (en) 2008-02-08 2015-03-18 MedImmune, LLC Disease markers and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CA2772921A1 (en) 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SG193446A1 (en) 2011-03-15 2013-10-30 Biogen Idec Inc Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
US8729236B2 (en) * 2011-05-23 2014-05-20 Hal S. Padgett Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
EP3924383A1 (en) 2019-02-15 2021-12-22 Astrazeneca AB Type i interferon-mediated disorders
KR102594862B1 (ko) * 2023-06-14 2023-10-27 (주) 신성하이스킬 화재방지 파쇄 시스템
KR102570958B1 (ko) * 2023-06-14 2023-08-25 (주) 신성하이스킬 화재방지 4축 파쇄장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR73557B (xx) * 1980-01-08 1984-03-15 Biogen Inc
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
EP0098876A1 (en) * 1982-01-19 1984-01-25 Cetus Corporation Multiclass hybrid interferons
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
EP0146903A3 (en) * 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4716217A (en) * 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
EP0173935A1 (en) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons

Also Published As

Publication number Publication date
GR861497B (en) 1986-10-10
DK272986A (da) 1986-12-12
US4885166A (en) 1989-12-05
PT82736B (pt) 1988-12-15
IE57865B1 (en) 1993-05-05
EP0205404A3 (en) 1987-10-21
KR870000427A (ko) 1987-02-18
NO175602C (no) 1994-11-02
ATE78262T1 (de) 1992-08-15
DE3685996T2 (de) 1993-01-14
PT82736A (en) 1986-07-01
FI862461A0 (fi) 1986-06-09
JPH0736757B2 (ja) 1995-04-26
FI862461A (fi) 1986-12-12
NZ216485A (en) 1991-06-25
HU203255B (en) 1991-06-28
HUT41846A (en) 1987-05-28
JPH05308973A (ja) 1993-11-22
NO175602B (no) 1994-07-25
IL79085A (en) 1992-03-29
DE3685996D1 (de) 1992-08-20
SG25195G (en) 1995-08-18
CA1285507C (en) 1991-07-02
JPH0655759B2 (ja) 1994-07-27
DK168794B1 (da) 1994-06-13
EP0205404B1 (en) 1992-07-15
US5071761A (en) 1991-12-10
IE861542L (en) 1986-12-11
NO862313D0 (no) 1986-06-10
FI90983C (fi) 1994-04-25
HK99895A (en) 1995-06-30
AU598196B2 (en) 1990-06-21
KR920002267B1 (ko) 1992-03-20
JPS626000A (ja) 1987-01-12
EP0205404A2 (en) 1986-12-17
FI90983B (fi) 1994-01-14
NO862313L (no) 1986-12-12
AU5849986A (en) 1986-12-18
DK272986D0 (da) 1986-06-10
IL79085A0 (en) 1986-09-30

Similar Documents

Publication Publication Date Title
EP0205404A3 (en) Hybrid interferons
DE3684342D1 (de) Ballistisch widerstandsfaehiges zusammengesetztes erzeugnis.
ES8500996A1 (es) Meotod de producir un polipeptido.
GB2121474B (en) Two-stage i.c. engine turbocharging
IE851906L (en) Interferons
GR3033769T3 (en) Human interferon beta2A, vectors containing genes coding for said interferon, cell lines producing same.
NZ228105A (en) Antihypertensive hyperimmune milk, its production and medicaments therefrom
EP0315637A4 (en) POLYPEPTIDES USEFUL IN THE DIAGNOSIS OF MYCOPLASMA INFECTIONS IN PIGS, AND RECOMBINANT DNA METHODS FOR THEIR MANUFACTURE.
AU598460B2 (en) Process preparing and purifying interferon
ES8404373A1 (es) Un procedimiento para obtener compuestos de ribofuranosilselenazol-4-carboxamida.
ES2001108A6 (es) Un procedimiento para la preparacion de un derivado de gem-dihalo-1,8-diamino -4 -aza-octano.
EP0276120A3 (en) Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
JPS57158796A (en) Hybrid human leukocyte interferon
ZA877417B (en) Novel lymphokine related peptides
SU939352A1 (ru) Двухмассный вибрационный конвейер
IT8321847A1 (it) Procedimento per la preparazione di antibiotici del gruppo antracicline con attivita' anti-cancro, e nuovo ceppo di microrganismi
SG134394G (en) Genetic sequences, type I interferon peptide coded by them, and these organisms producing the same
HUT50562A (en) Novel hybrid maize sort